Published in PLoS One on April 28, 2016
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol (1998) 9.32
The friction cost method for measuring indirect costs of disease. J Health Econ (1995) 5.55
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol (2001) 5.28
Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making (1998) 5.14
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2014) 2.75
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol (2014) 2.55
Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. Breast J (2004) 1.89
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol (2011) 1.59
Health state utilities for non small cell lung cancer. Health Qual Life Outcomes (2008) 1.56
Health state utilities for metastatic breast cancer. Br J Cancer (2006) 1.50
Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol (2012) 1.43
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J (2006) 1.36
Costs of heart failure-related hospitalizations in patients aged 18 to 64 years. Am J Manag Care (2010) 1.25
Health related quality of life in different states of breast cancer. Qual Life Res (2007) 1.24
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res (2013) 1.23
Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst (2001) 1.18
Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer (2010) 1.15
Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med (2011) 1.14
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer (2010) 1.12
Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat (2012) 1.10
Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? J Clin Oncol (2014) 1.09
Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist (2001) 1.04
Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study. J Cancer Res Clin Oncol (2008) 1.02
Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care (2007) 1.00
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast (2013) 0.97
Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res (2014) 0.96
Imaging of triple-negative breast cancer. Ann Oncol (2012) 0.95
Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit? Breast (2013) 0.95
Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol (2008) 0.89
18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Acta Radiol (2012) 0.87
Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open (2012) 0.84
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2013) 0.79
Anthropometric reference data for elderly Swedes and its disease-related pattern. Eur J Clin Nutr (2015) 0.79
Quality of life among women treated for breast cancer: a survey of three procedures in Mexico. Aesthetic Plast Surg (2014) 0.77
Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? Reply to K.-D. Yu et al. J Clin Oncol (2014) 0.76
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (2014) 9.66
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol (2016) 1.84
Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib. J Clin Oncol (2014) 1.13
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res (2014) 0.89
Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast (2015) 0.89
Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care (Basel) (2014) 0.88
The importance of supportive care in breast cancer patients. Breast Care (Basel) (2014) 0.78
Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol (2015) 0.77
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res (2016) 0.77
Pathological complete response in breast cancer--authors' reply. Lancet (2015) 0.76
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet (2016) 0.76
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol (2017) 0.75
Current approach of the axilla in patients with early-stage breast cancer. Lancet (2017) 0.75